Brief: 3SBio Says Unit Entered Exclusive Commercialization Cooperation Agreement

3SBio

24/10/2024 10:29

Oct 24 (Reuters) - 3SBio Inc  1530.HK :
    * UNIT ENTERED INTO PACLITAXEL ORAL SOLUTION EXCLUSIVE
COMMERCIALIZATION COOPERATION AGREEMENT
    * COOPERATION AGREEMENT WITH SHANGHAI HAIHE BIOPHARMA
RESEARCH AND
DEVELOPMENT, OTHERS
    * SHENYANG SUNSHINE WILL OBTAIN EXCLUSIVE COMMERCIALIZATION
RIGHTS
OF RMX BIOPHARMA'S PRODUCT OF PACLITAXEL ORAL SOLUTION

Further company coverage:  1530.HK 

 ((Reuters.Briefs@thomsonreuters.com;))